Abera Bioscience AB (NGM:ABERA)

Market Cap	120.16M +81.6%
Revenue (ttm)	17.30M +37.2%
Net Income	-1.45M
EPS	-0.09
Shares Out	18.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	137,225
Average Volume	28,851
Open	5.90
Previous Close	6.00
Day's Range	5.60 - 6.60
52-Week Range	3.72 - 9.70
Beta	0.96
RSI	57.13
Earnings Date	Feb 12, 2026

About Abera Bioscience AB

Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC,...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 5
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: ABERA

Financial Performance

In 2024, Abera Bioscience AB's revenue was 14.63 million, an increase of 479.60% compared to the previous year's 2.52 million. Losses were -1.10 million, -93.42% less than in 2023.